COYA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.21 USD | -2.96% |
|
-5.41% | +10.80% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 12.27 | 106.7 | 119.9 | - | - |
| Enterprise Value (EV) 1 | 12.27 | 106.7 | 119.9 | 119.9 | 119.9 |
| P/E ratio | -1 x | -9.38 x | -7.4 x | -4.64 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 17.8 x | 22.8 x | 12 x | 4 x |
| EV / Revenue | - | 17.8 x | 22.8 x | 12 x | 4 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,590 | 14,401 | 14,602 | - | - |
| Reference price 2 | 4.738 | 7.410 | 8.210 | 8.210 | 8.210 |
| Announcement Date | 3/29/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 6 | 5.264 | 10 | 30 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -9.812 | -7.903 | -16.97 | -28.26 | - |
| Operating Margin | - | - | -131.72% | -322.35% | -282.62% | - |
| Earnings before Tax (EBT) 1 | - | -12.24 | -7.264 | -16.22 | -28.04 | - |
| Net income 1 | -4.892 | -12.24 | -7.988 | -16.22 | -28.04 | - |
| Net margin | - | - | -133.13% | -308.25% | -280.41% | - |
| EPS 2 | -0.3300 | -4.730 | -0.7900 | -1.110 | -1.770 | - |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/18/22 | 3/29/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales | - | - | - | 6 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.9 | -2.904 | -3.564 | 1.815 | - | -1.778 | -2.428 | -7.278 |
| Operating Margin | - | - | - | 30.25% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.095 | -3.422 | 1.99 | - | -1.67 | -2.324 | -7.179 |
| Net income | -2.736 | -3.095 | -3.422 | 1.266 | -5.052 | - | - | - |
| Net margin | - | - | - | 21.1% | - | - | - | - |
| EPS 2 | -0.2800 | -0.3100 | -0.3400 | 0.1500 | -0.3500 | -0.1100 | -0.1600 | -0.4900 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/10/23 | 8/8/23 | 11/8/23 | 3/19/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 11/18/22 | 3/29/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.21
USD
Average target price
14.5
USD
Spread / Average Target
+76.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.80% | 120M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- COYA Stock
- Financials Coya Therapeutics, Inc.